Physician profile
Mark C Jacobson
NPI 1124059076
$14,273.81
in general payments reported to CMS, 2019-2025
34 companies · $4,037 in 2025
The $4,037 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,264 · 2020: $1,253 · 2021: $1,627 · 2022: $1,485 · 2023: $1,635 · 2024: $1,973 · 2025: $4,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,877 · Consulting Fee: $1,719 · Travel and Lodging: $49.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,876.91 |
| Consulting Fee | $1,719.00 |
| Travel and Lodging | $49.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,244.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,467.86 | 2019-2025 | Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,397.10 | 2019-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $1,325.25 | 2019-2025 | |
| Csl Behring | $1,199.43 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Regeneron Healthcare Solutions, INC. | $1,197.55 | 2019-2025 | Dupixent |
| Pfizer INC. | $623.58 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $537.97 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Genentech USA, INC. | $448.77 | 2019-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $443.02 | 2019-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.74 | 2019-2022 | |
| Alk-Abello, INC | $229.52 | 2019-2022 | |
| Kaleo, INC. | $219.67 | 2019-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $209.59 | 2023-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $190.46 | 2021-2025 | Orladeyo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $185.49 | 2025 | Neffy |
| Amgen INC. | $172.46 | 2021-2025 | Actimmune, Tezspire |
| Covis Pharma Gmbh | $119.46 | 2019-2021 | |
| Pharming Healthcare, INC. | $89.57 | 2022-2024 | Ruconest |
| Hikma Pharmaceuticals USA | $87.31 | 2023-2025 | Ryaltris |
| Shire North American Group INC | $80.28 | 2019 | |
| Leo Pharma INC. | $75.30 | 2022-2023 | Adbry |
| Bio Products Laboratory USA, INC. | $68.55 | 2021-2023 | Gammaplex, Coagadex |
| Octapharma USA, INC. | $59.13 | 2024 | Panzyga |
| Optinose US, INC. | $55.65 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $46.89 | 2019-2023 | |
| Phadia US INC. | $43.18 | 2019-2023 | Immunocap |
| Lilly USA, LLC | $41.05 | 2019-2025 | Ebglyss |
| Aimmune Therapeutics, INC. | $37.19 | 2022 | |
| Incyte Corporation | $25.66 | 2024 | Opzelura |
| Abbvie INC. | $24.70 | 2025 | |
| Biocryst Pharmaceuticals, INC. | $22.85 | 2020 | |
| Greer Laboratories, INC. | $19.86 | 2025 | Oralair |
| Mylan Pharmaceuticals INC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.